The Kaplan-Meier curves revealed that high ARPC5 expression predicts a poor prognosis for patients with grade II and III gliomas, and the same result was obtained for different molecular subtypes, such as gender, age, IDH mutation status, 1p/19q co-deletion status, and MGMT methylated status. Here, ARPC5 is linked to central nervous system cancer.